Phase I trial of NLX E201, a gene therapy for the treatment of epilepsy

Trial Profile

Phase I trial of NLX E201, a gene therapy for the treatment of epilepsy

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2007

At a glance

  • Drugs NLX E201 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Dec 2007 Neurologix has received a grant from the Epilepsy Research Foundation and will use it to fund this trial which is expected to begin in early 2008.
    • 15 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top